[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Aryan HE, Meltzer HS, Lu DC, Ozgur BM, Levy ML, Bruce DA: Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Childs Nerv Syst; 2005 Jun;21(6):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
  • INTRODUCTION: Leptomeningeal dissemination of juvenile pilocytic astrocytoma (JPA) is a rare event.
  • We report two children with disseminated JPAs treated with a chemotherapeutic agent, temozolomide, after progression of the disease despite surgery, traditional chemotherapy, and/or radiation therapy.
  • [MeSH-major] Arachnoid Cysts / therapy. Astrocytoma / therapy. Brain Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Child. Child, Preschool. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Magnetic Resonance Imaging / methods. Neurosurgery. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Diffuse Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurosurg Rev. 1996;19(4):217-20 [9007882.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2671-3 [8194003.001]
  • [Cites] Childs Brain. 1976;2(3):177-86 [971637.001]
  • [Cites] Neurology. 1976 Apr;26(4):322-5 [944389.001]
  • [Cites] Clin Neuropathol. 1988 Sep-Oct;7(5):254-8 [3208464.001]
  • [Cites] J Neurosurg. 1978 Jan;48(1):34-41 [412924.001]
  • [Cites] Neurology. 1988 Apr;38(4):562-6 [3352911.001]
  • [Cites] Cancer. 1993 May 15;71(10 ):3165-72 [8490847.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1000-4 [2434201.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):47-54 [8865002.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):128-32 [7463115.001]
  • [Cites] Br J Neurosurg. 1998 Feb;12(1):56-8 [11013652.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):300-6 [8599896.001]
  • [Cites] J Neurooncol. 2002 May;57(3):247-51 [12125988.001]
  • [Cites] Childs Brain. 1983;10(6):393-403 [6661937.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Surg Neurol. 1997 Jul;48(1):49-51; discussion 51-2 [9199684.001]
  • [Cites] Childs Nerv Syst. 1993 Sep;9(6):334-8 [8269416.001]
  • [Cites] J Neurosurg. 1991 Dec;75(6):972-5 [1941128.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14(11):617-22 [9840361.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):115-27 [11716065.001]
  • [Cites] J Neurosurg. 1992 Nov;77(5):788-91 [1403124.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14 ):1788-95 [10974627.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):223-7 [8331404.001]
  • (PMID = 15378329.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 34
  •  go-up   go-down


2. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer; 2010 Oct;55(4):668-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, AZD6244 was evaluated against two juvenile pilocytic astrocytoma (JPA) xenografts using once and twice daily dosing schedules.
  • AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] BRAF).
  • CONCLUSIONS: At the dose and schedule of administration used, AZD6244 as a single agent had limited in vitro and in vivo activity against the PPTP tumor panels despite inhibition of MEK1/2 activity.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4286-93 [19401449.001]
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):639-44 [19853943.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6 [19915144.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1613-23 [20179232.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Hematol J. 2002;3(3):157-63 [12111653.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1269-72 [15547749.001]
  • [Cites] Acta Neuropathol. 2004 Dec;108(6):467-70 [15517309.001]
  • [Cites] Leukemia. 2005 Feb;19(2):310-2 [15538400.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):223-34 [16397046.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):646-9 [16434186.001]
  • [Cites] BMC Cancer. 2006;6:177 [16822308.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1576-83 [17332304.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):886-97 [17363483.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1620-8 [17483438.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2209-19 [17699718.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11300-8 [18056456.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):230-9 [18172275.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]
  • (PMID = 20806365.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CM / N01-CM-42216; United States / NCI NIH HHS / CA / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AZD 6244; 0 / Benzimidazoles; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  • [Other-IDs] NLM/ NIHMS218595; NLM/ PMC3004092
  •  go-up   go-down


3. Foreman NK, Gore L, Wells D, Straessle J, Heideman R, Donson AM: Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. Pediatr Blood Cancer; 2006 Sep;47(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
  • BACKGROUND: Juvenile pilocytic astrocytomas (JPAs) are the most common central nervous system tumors in children.
  • PROCEDURE: Due to a lack of established cell-lines of JPA very few in vitro drug sensitivity assays have been performed.
  • CONCLUSIONS: Based on these preclinical data, gefitinib may be a suitable salvage chemotherapy drug to explore further in those patients with JPA who have recurred after primary chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Flow Cytometry. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Thymidine / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206208.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA49981
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; VC2W18DGKR / Thymidine
  •  go-up   go-down


Advertisement
4. Walter AW, Gajjar A, Reardon DA, Thompson SJ, Langston JW, Jones-Wallace D, Kun LE, Heideman RL: Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol; 2000 May-Jun;22(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1).
  • Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10864056.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P01 CA-23099; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


5. Gillerman R, Duncan J, Bolton J: Prolonged somatosensory evoked potential depression following a brief exposure to low concentrations of inhalation anaesthetic in a 3-year-old child. Paediatr Anaesth; 2000;10(3):336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 3-year-old child was brought to the operating room for removal of a brainstem juvenile pilocytic astrocytoma.
  • Somatosensory evoked potentials (SSEPs) were recorded but unobtainable initially and up to 90 min after all inhalation agents were discontinued.
  • [MeSH-minor] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Child, Preschool. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Depression.
  • Hazardous Substances Data Bank. Isoflurane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792753.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; CYS9AKD70P / Isoflurane
  •  go-up   go-down


6. Menon PM, Gutierrez JA, Rempel SA: A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol; 2000 Oct;17(4):683-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SPARC is a secreted glycoprotein that interacts with extracellular matrix (ECM) proteins to promote de-adhesion of cells from the matrix, thereby inducing a biological state conducive to cell migration.
  • We have demonstrated that SPARC is highly expressed in gliomas (grades II-IV) and promotes glioma invasion in vitro.
  • In this study, we immuno-histochemically determined if the grade I juvenile pilocytic astrocytomas (JPAs) also express SPARC, if vitronectin is expressed in grades I, II, and IV astrocytomas, and if the proteins colocalize in brain tumors in vivo.
  • [MeSH-minor] Adult. Blotting, Western. Cell Movement / drug effects. Child. Dose-Response Relationship, Drug. Humans. Immunohistochemistry. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10995878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


7. Silva MM, Goldman S, Keating G, Marymont MA, Kalapurakal J, Tomita T: Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy. Pediatr Neurosurg; 2000 Sep;33(3):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination revealed low-grade astrocytoma in 5 and juvenile pilocytic astrocytoma in 4.
  • All patients received chemotherapy: carboplatin in 8, a combination of carboplatin and vincristine in 4 and a combination of other agents in 2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypothalamic Neoplasms / diagnosis. Hypothalamic Neoplasms / drug therapy. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / drug therapy
  • [MeSH-minor] Astrocytoma / drug therapy. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11096362.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Hayashi S, Nanaumi A, Akiba Y, Komiyama T, Takeuchi K: Collection of medical drug information in pharmacies: Drug Event Monitoring (DEM) in Japan. Yakugaku Zasshi; 2005 Jul;125(7):555-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collection of medical drug information in pharmacies: Drug Event Monitoring (DEM) in Japan.
  • To establish a system for collecting and reporting information from community pharmacists such as that on adverse effects, the Japan Pharmaceutical Association (JPA) conducts Drug Event Monitoring (DEM).
  • In the fiscal year 2002, a survey was carried out to clarify the incidence of sleepiness due to antiallergic drugs.
  • Community pharmacists asked the following question to patients who visited their pharmacies: "Have you ever become sleepy after taking this drug?
  • To evaluate the incidence of sleepiness, we analyzed cases in which reports showed alleged absence of concomitant oral drugs, and drug use in conformity with the dose and method described in package inserts.
  • The incidence of sleepiness was significantly different among the drugs (chi(2)-test, p<0.001).
  • The observed incidences of sleepiness due to the drugs (8.8-20.5%) were higher than those described in each package insert (1.8-6.35%).
  • This may be because an active question was used ("Have you ever become sleepy after taking this drug? ").
  • [MeSH-major] Adverse Drug Reaction Reporting Systems. Community Pharmacy Services. Drug Information Services. Drug Monitoring
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Allergic Agents / adverse effects. Child. Disorders of Excessive Somnolence / chemically induced. Female. Humans. Japan. Male. Middle Aged. Quality of Life. Societies, Pharmaceutical / organization & administration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997212.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Allergic Agents
  •  go-up   go-down


9. Pfeiffer T, Rand DG, Dreber A: Decision-making in research tasks with sequential testing. PLoS One; 2009;4(2):e4607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a recent controversial essay, published by JPA Ioannidis in PLoS Medicine, it has been argued that in some research fields, most of the published findings are false.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12052-6 [17620606.001]
  • [Cites] JAMA. 2007 Dec 5;298(21):2517-26 [18056905.001]
  • [Cites] Nat Genet. 2008 Sep;40(9):1047-51 [18728691.001]
  • [Cites] Q J Exp Psychol. 1968 Aug;20(3):273-81 [5683766.001]
  • [Cites] Am J Public Health. 1988 Dec;78(12):1568-74 [3189634.001]
  • [Cites] Mem Cognit. 1992 Jul;20(4):392-405 [1495401.001]
  • [Cites] Int J Epidemiol. 2007 Apr;36(2):445-8 [17470492.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):218-28 [16014596.001]
  • [Cites] PLoS Med. 2005 Aug;2(8):e124 [16060722.001]
  • [Cites] Psychol Rev. 2005 Oct;112(4):979-99 [16262476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4940-5 [16543380.001]
  • [Cites] Curr Biol. 2006 Nov 21;16(22):R946-9 [17113371.001]
  • [Cites] J Clin Epidemiol. 2005 Jun;58(6):543-9 [15878467.001]
  • (PMID = 19240797.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2643008
  •  go-up   go-down






Advertisement